Becton Dickinson and Co (NYSE:BDX) Stock Position Decreased by Tredje AP fonden

Tredje AP fonden cut its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,688 shares of the medical instruments supplier’s stock after selling 307 shares during the quarter. Tredje AP fonden’s holdings in Becton Dickinson and were worth $4,223,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BDX. Wealth Quarterback LLC acquired a new stake in shares of Becton Dickinson and in the fourth quarter worth $7,588,711,000. FMR LLC boosted its position in shares of Becton Dickinson and by 4.1% in the fourth quarter. FMR LLC now owns 13,465,704 shares of the medical instruments supplier’s stock worth $3,662,267,000 after buying an additional 528,037 shares during the period. State Street Corp boosted its position in shares of Becton Dickinson and by 1.7% in the fourth quarter. State Street Corp now owns 11,450,583 shares of the medical instruments supplier’s stock worth $3,114,215,000 after buying an additional 186,285 shares during the period. Geode Capital Management LLC boosted its position in shares of Becton Dickinson and by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 3,692,242 shares of the medical instruments supplier’s stock worth $1,001,837,000 after buying an additional 124,664 shares during the period. Finally, Fiera Capital Corp boosted its position in shares of Becton Dickinson and by 4.7% in the first quarter. Fiera Capital Corp now owns 3,615,334 shares of the medical instruments supplier’s stock worth $830,695,000 after buying an additional 160,738 shares during the period. 86.79% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently commented on the company. Morgan Stanley decreased their target price on Becton Dickinson and from $271.00 to $255.00 and set an “equal weight” rating for the company in a research report on Friday, March 27th. Raymond James lifted their price objective on Becton Dickinson and from $283.00 to $290.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Cowen cut Becton Dickinson and from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $306.00 to $275.00 in a research report on Thursday, February 6th. KeyCorp reissued a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, May 12th. Finally, Piper Sandler lifted their price objective on Becton Dickinson and from $286.00 to $296.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Nine research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Becton Dickinson and has a consensus rating of “Hold” and an average target price of $275.79.

NYSE BDX traded up $0.31 during trading on Friday, hitting $239.25. 11,783,270 shares of the company traded hands, compared to its average volume of 1,932,654. Becton Dickinson and Co has a 12 month low of $197.75 and a 12 month high of $286.72. The business has a fifty day simple moving average of $253.35 and a 200 day simple moving average of $255.35. The company has a current ratio of 0.98, a quick ratio of 0.66 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $64.79 billion, a P/E ratio of 72.06, a PEG ratio of 2.57 and a beta of 0.95.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.23. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The business had revenue of $4.25 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the previous year, the company posted $2.59 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Equities research analysts predict that Becton Dickinson and Co will post 10.5 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date is Monday, June 8th. Becton Dickinson and’s payout ratio is 27.05%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: How can you know how many shares are floating?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.